Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gamida Cell Ltd
(NQ:
GMDA
)
0.0327
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gamida Cell Ltd
< Previous
1
2
3
Next >
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
November 10, 2022
From
Gamida Cell Ltd.
Via
Business Wire
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
November 07, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
November 07, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
November 03, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
October 10, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
September 29, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
September 28, 2022
From
Gamida Cell
Via
Business Wire
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
September 28, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
September 27, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
September 19, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
September 12, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
August 15, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
August 10, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
August 08, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
August 01, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
June 13, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
June 10, 2022
From
Gamida Cell
Via
Business Wire
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
June 02, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
June 01, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
June 01, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
May 17, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
May 10, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
May 05, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
May 03, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
April 27, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
April 26, 2022
From
Gamida Cell
Via
Business Wire
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
April 25, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
April 25, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
April 07, 2022
From
Gamida Cell Ltd.
Via
Business Wire
Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
March 15, 2022
From
Gamida Cell Ltd.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.